Skye Bioscience announces new preclinical data for nimacimab

Skye Bioscience (SKYE) announced new preclinical data for its novel CB1 antibody, nimacimab. In a murine diet-induced obesity model, after 25 days of treatment, results demonstrated: Greater than 30% weight loss when nimacimab was combined with the dual GLP-1/GIP agonist, tirzepatide; Nimacimab alone demonstrated 23.5% weight loss, comparable to monlunabant and tirzepatide alone. “This new preclinical study highlights that a truly peripherally-restricted CB1 inhibitor-nimacimab-effectively drives weight loss in a DIO model. Nimacimab compared favorably to and provided significant additive weight loss when combined with GLP-1-targeted drugs like tirzepatide,” said Punit Dhillon, CEO of Skye. “Using higher doses, this study builds on our previous preclinical DIO data in human CB1 knock-in mice that showed significant dose-dependent weight loss. Biomarker analyses demonstrated that nimacimab-driven weight loss was associated with beneficial changes in key hormones, glycemic control, and inflammatory markers.